Literature DB >> 1650217

Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system. A possible correlation with their anti-inflammatory properties.

J M van Zyl1, K Basson, A Kriegler, B J van der Walt.   

Abstract

The mechanisms by which two anti-leprotic drugs (clofazimine and dapsone), both with anti-inflammatory properties, inhibit myeloperoxidase (MPO)-catalysed reactions, were investigated. The disappearance of NADH fluorescence was used as an assay for its oxidation. Chloride stimulated the oxidation of NADH in the MPO-H2O2 system in a concentration-dependent manner (50-fold at 150 mM NaCl). Under these conditions Cl- is oxidized and the oxidant formed, presumably hypochlorous acid (HOCl), oxidizes NADH. Observations demonstrating the effect of the drugs on the MPO system, are: (1) Inhibition of Cl(-)-stimulated oxidation of NADH. (2) Inhibition of polypeptide modification in a model protein, thyroglobulin (TG). (3) Protection of MPO against loss of catalytic activity caused by chlorinating oxidants generated by the system. (4) Inhibition of haemoglobin oxidation. Only dapsone was active here. HPLC analyses suggested that the drugs were not significantly metabolized in the MPO-H2O2 system in the absence of Cl-. Bleaching of clofazimine was stimulated by Cl- in the MPO system, suggesting the involvement of HOCl. Clofazimine was found to be a more potent scavenger of HOCl than dapsone when the inhibition of NADH oxidation by reagent HOCl was used as an assay. This finding is also supported by HPLC analyses which indicated a greater sensitivity of HOCl for clofazimine than for dapsone. Relatively low concentrations of dapsone inhibited the oxidation of oxygenated haemoglobin (HbO2), suggesting that the drug was not metabolized to its N-hydroxylated derivative which is thought to be responsible for methaemoglobin (metHb) formation in vivo. It is proposed that the inhibitory mechanism of action of clofazimine is to scavenge chlorinating oxidants generated by the MPO-Cl(-)-H2O2 system, while dapsone converts MPO into its inactive compound II (ferryl) form. The different inhibitory mechanisms of clofazimine and dapsone towards the MPO system may contribute to the anti-inflammatory actions of the drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650217     DOI: 10.1016/0006-2952(91)90323-w

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Immunomodulation by antibacterial agents. Is it clinically relevant?

Authors:  M T Labro
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 3.  Dapsone in dermatology and beyond.

Authors:  Gottfried Wozel; Christian Blasum
Journal:  Arch Dermatol Res       Date:  2013-12-06       Impact factor: 3.017

4.  NADPH as a co-substrate for studies of the chlorinating activity of myeloperoxidase.

Authors:  F Auchère; C Capeillère-Blandin
Journal:  Biochem J       Date:  1999-11-01       Impact factor: 3.857

5.  Peroxidative metabolism of beta2-agonists salbutamol and fenoterol and their analogues.

Authors:  Krzysztof J Reszka; Dennis W McGraw; Bradley E Britigan
Journal:  Chem Res Toxicol       Date:  2009-06       Impact factor: 3.739

6.  4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.

Authors:  Jong-Hoon Lee; Ha Kyeu An; Mun-Gi Sohn; Paul Kivela; Sangsuk Oh
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

7.  Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions.

Authors:  Douglas Walker; Lih-Fen Lue
Journal:  Curr Neuropharmacol       Date:  2007-12       Impact factor: 7.363

8.  Recovery of Dementia Syndrome following Treatment of Brain Inflammation.

Authors:  Jong-Hoon Lee; Su-Hee Choi; Chul Joong Lee; Sang-Suk Oh
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2020-01-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.